Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

MidOStaurin + Gemtuzumab OzogAmIcin Combination in First-line Standard Therapy for Acute Myeloid Leukemia (MOSAIC)

NCT04385290 is registered in ClinicalTrials.gov with Technische Universität Dresden as lead sponsor.

NCT NCT04385290
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04385290 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
MidOStaurin + Gemtuzumab OzogAmIcin Combination in First-line Standard Therapy for Acute Myeloid Leukemia (MOSAIC)
Lead sponsor
Technische Universität Dresden
Phase
Phase 1/2
Overall status
Recruiting
Start date
September 4, 2020
Completion date
April 30, 2028
Enrollment
214 (estimated)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia